Related Experiment Videos
Rapamycin inhibits aldolase A expression during human lymphocyte activation
1Laboratory of Transplantation Immunology, Louis-Charles Simard Research Center, Notre-Dame Hospital, Montreal, Quebec, Canada.
Journal of Cellular Biochemistry
|November 1, 1996
Summary
Rapamycin (RAPA) inhibits lymphocyte activation by repressing aldolase A, a key glycolytic enzyme. This mechanism may limit energy supply, hindering lymphocyte proliferation.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- Rapamycin (RAPA) inhibits lymphocyte activation and proliferation.
- Its precise molecular mechanisms, particularly gene expression effects, remain incompletely understood.
Purpose of the Study:
- To identify RAPA-sensitive genes involved in lymphocyte signaling.
- To elucidate the role of aldolase A in RAPA's immunosuppressive effects.
Main Methods:
- Differential hybridization screening for RAPA-sensitive genes.
- Analysis of human aldolase A gene expression during T and B cell activation.
- Assessment of RAPA, cyclosporin A, and FK506 effects on aldolase A expression.
- Cell cycle analysis of Jurkat cells treated with RAPA.
Main Results:
- Human aldolase A gene expression is induced during T and B cell activation.
- RAPA, cyclosporin A, and FK506 repressed this induction at mRNA and enzyme levels.
- RAPA inhibited aldolase A expression in the second cell cycle post-synchronization.
- Aldolase A induction was not observed during the cell cycle or in the first cycle.
Conclusions:
- Aldolase A is a potential downstream target of RAPA in lymphocytes.
- RAPA-mediated inhibition of aldolase A may impair glycolysis and energy supply.
- This energy depletion could contribute to RAPA's inhibition of lymphocyte proliferation.